KRAS-Mutant non-small cell lung cancer: From biology to therapy

Irene Ferrer,Jon Zugazagoitia, Stephan Herbertz,William J. John,Luis Paz-Ares,Gerald Schmid-Bindert

Lung Cancer（2018）

引用 246|浏览14

暂无评分

摘要

•In Western countries, the most frequent oncogene driver mutation in NSCLC is KRAS.•The biological heterogeneity of KRAS-mutant NSCLC imposes many treatment challenges.•We provide an update on molecularly driven therapies for this disease.•Recent data suggest that immunotherapy may be a promising treatment approach.•Treatment for KRAS-mutant NSCLC will need to be individualised in the future.

查看译文

关键词

BATTLE,BET,CDK,Chk1,CI,CUSTOM,DDR1,EGFR,ERK,FAK,FGFR,FOXO,GAPs,GEFs,GGTase,HIF1α,HR,HRAS,ICMT,IFN,IL,JNK,JUNIPER,KRAS,MAPK,MEK,MISSION,MK2,mTOR,NF,NRF2,NSCLC,OR,ORRs,OS,PDK1,PD-L1,PFS,PIP2,PIP3,PI3K,RAS,RCE1,RHOA,SELECT-1,shRNA,siRNA,TAILOR,TKIs,TORCMEK,TTF-1

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要